{"id":"W2801721440","doi":"10.1007/s11899-018-0449-7","title":"Tyrosine Kinase Inhibitors in the Treatment of Chronic-Phase CML: Strategies for Frontline Decision-making","year":2018,"lang":"en","type":"review","venue":"Current Hematologic Malignancy Reports","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Bosutinib; Nilotinib; Dasatinib; Medicine; Imatinib; Oncology; Disease; Tyrosine kinase; Imatinib mesylate; Tyrosine-kinase inhibitor; Internal medicine; Myeloid leukemia; Toxicity; Pharmacology; Intensive care medicine; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000618639,0.001149988,0.004421451,0.0004622164,0.0001253055,0.0000555824,0.0003091529,0.0005404822,0.000148856],"category_scores_gemma":[0.0004287186,0.0006400202,0.001493682,0.0006364395,0.0002663317,0.0001104575,0.0000790292,0.0003053754,0.00001738025],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002312282,"about_ca_system_score_gemma":0.003308479,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002568282,"about_ca_topic_score_gemma":0.00005534336,"domain_scores_codex":[0.9936889,0.0001823548,0.003346301,0.001336576,0.0006482787,0.0007975989],"domain_scores_gemma":[0.9941503,0.0009516115,0.002589106,0.001941061,0.0002257978,0.0001420788],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001140621,0.005416133,0.0001622694,0.03110781,0.0003098198,0.004231449,0.0002627292,0.000001187937,0.000001154269,0.0002844291,0.003458973,0.95465],"study_design_scores_gemma":[0.003863148,0.003311185,0.000006553696,0.1040403,0.002911029,0.004743894,0.00009474147,0.00003770668,0.00004192026,0.001424442,0.8789709,0.000554223],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.002819352,0.9866053,0.0004377486,0.00002087088,0.001853809,0.00787125,0.0001247006,0.00008386893,0.000183106],"genre_scores_gemma":[0.008243018,0.9866268,0.0009605885,0.000008559495,0.0007610067,0.002501038,0.0007533219,0.0001024686,0.00004318358],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9540958,"threshold_uncertainty_score":0.9996051,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07998761122677826,"score_gpt":0.4216340902875697,"score_spread":0.3416464790607914,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}